BioSpace News Archive

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in two upcoming investor conferences.

Synthego, the genome engineering company, today announced it has raised $200 million of growth capital, including a Series E financing led by Perceptive Advisors.

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, February 24, 2022.

ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships.

EvoEndo®, Inc. has announced the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) to begin marketing and sale of the EvoEndo® Single-Use Endoscopy System.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the approval of four generic injectables products.

Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens.

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, announced that it is exploring strategic alternatives with the goal of enhancing shareholder value.

Entera Bio Ltd today announced that the Company’s Chief Executive Officer, Spiros Jamas, Sc.D., will present a company overview at the Aegis Capital Corp. Virtual Conference on February 23rd at 3:30 PM Eastern time.

Lupin Pharmaceuticals Inc., (Lupin) today announced that the U.S. Food and Drug Administration has approved the company’s supplemental New Drug Application (sNDA) to expand the use of SOLOSEC®.